Hayder M Al-Kuraishy1, Ali I Al-Gareeb1, M Alblihed2, Natália Cruz-Martins3,4,5, Gaber El-Saber Batiha6. 1. Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq. 2. Department of Microbiology, College of Medicine, Taif University, Taif, Saudi Arabia. 3. Faculty of Medicine, University of Porto, Porto, Portugal. 4. Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal. 5. Laboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto, Porto, Portugal. 6. Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Abstract
Background: Coronavirus disease 19 (COVID-19) is regarded as an independent risk factor for acute ischemic stroke (AIS) due to the induction of endothelial dysfunction, coagulopathy, cytokine storm, and plaque instability. Method: In this retrospective cohort study, a total of 42 COVID-19 patients with type 2 diabetes mellitus (T2DM) who presented with AIS within 1 week of displaying COVID-19 symptoms were recruited. According to the current anti-DM pharmacotherapy, patients were divided into two groups: a Metformin group of T2DM patients with COVID-19 and AIS on metformin therapy (850 mg, 3 times daily (n = 22), and a Non-metformin group of T2DM patients with COVID-19 and AIS under another anti-DM pharmacotherapy like glibenclamide and pioglitazone (n = 20). Anthropometric, biochemical, and radiological data were evaluated. Results: Ferritin serum level was lower in metformin-treated patients compared to non-metformin treated patients (365.93 ± 17.41 vs. 475.92 ± 22.78 ng/mL, p = 0.0001). CRP, LDH, and D-dimer serum levels were also lowered in metformin-treated patients compared to non-metformin treated patients (p = 0.0001). In addition, lung CT scan scores of COVID-19 patients was 30.62 ± 10.64 for metformin and 36.31 ± 5.03 for non-metformin treated patients. Conclusion: Metformin therapy in T2DM patients was linked to a lower risk of AIS during COVID-19. Further studies are needed to observe the link between AIS in COVID-19 diabetic patients and metformin therapy.
Background: Coronavirus disease 19 (COVID-19) is regarded as an independent risk factor for acute ischemic stroke (AIS) due to the induction of endothelial dysfunction, coagulopathy, cytokine storm, and plaque instability. Method: In this retrospective cohort study, a total of 42 COVID-19patients with type 2 diabetes mellitus (T2DM) who presented with AIS within 1 week of displaying COVID-19 symptoms were recruited. According to the current anti-DM pharmacotherapy, patients were divided into two groups: a Metformin group of T2DM patients with COVID-19 and AIS on metformin therapy (850 mg, 3 times daily (n = 22), and a Non-metformin group of T2DM patients with COVID-19 and AIS under another anti-DM pharmacotherapy like glibenclamide and pioglitazone (n = 20). Anthropometric, biochemical, and radiological data were evaluated. Results: Ferritin serum level was lower in metformin-treated patients compared to non-metformin treated patients (365.93 ± 17.41 vs. 475.92 ± 22.78 ng/mL, p = 0.0001). CRP, LDH, and D-dimer serum levels were also lowered in metformin-treated patients compared to non-metformin treated patients (p = 0.0001). In addition, lung CT scan scores of COVID-19patients was 30.62 ± 10.64 for metformin and 36.31 ± 5.03 for non-metformin treated patients. Conclusion:Metformin therapy in T2DM patients was linked to a lower risk of AIS during COVID-19. Further studies are needed to observe the link between AIS in COVID-19diabeticpatients and metformin therapy.
Authors: J Donald Easton; Jeffrey L Saver; Gregory W Albers; Mark J Alberts; Seemant Chaturvedi; Edward Feldmann; Thomas S Hatsukami; Randall T Higashida; S Claiborne Johnston; Chelsea S Kidwell; Helmi L Lutsep; Elaine Miller; Ralph L Sacco Journal: Stroke Date: 2009-05-07 Impact factor: 7.914
Authors: Venugopal R Venna; Jun Li; Matthew D Hammond; Nickolas S Mancini; Louise D McCullough Journal: Eur J Neurosci Date: 2014-03-21 Impact factor: 3.386
Authors: Hayder M Al-Kuraishy; Ali I Al-Gareeb; Sadiq M Al-Hamash; Simona Cavalu; Maisra M El-Bouseary; Fatma I Sonbol; Gaber El-Saber Batiha Journal: Front Med (Lausanne) Date: 2022-06-17
Authors: Hayder M Al-Kuraishy; Ali I Al-Gareeb; M Alblihed; Susana G Guerreiro; Natália Cruz-Martins; Gaber El-Saber Batiha Journal: Front Cardiovasc Med Date: 2021-05-20
Authors: Amany Magdy Beshbishy; Victor B Oti; Diaa E Hussein; Ibrahim F Rehan; Oluyomi S Adeyemi; Nallely Rivero-Perez; Adrian Zaragoza-Bastida; Muhammad Ajmal Shah; Khaled Abouelezz; Helal F Hetta; Natália Cruz-Martins; Gaber El-Saber Batiha Journal: Front Public Health Date: 2021-07-07
Authors: Hayder M Al-Kuraishy; Ali I Al-Gareeb; Francis O Atanu; Mona A El-Zamkan; Hassan M Diab; Ahmed S Ahmed; Thabat J Al-Maiahy; Ahmad J Obaidullah; Sultan Alshehri; Mohammed M Ghoniem; Gaber E Batiha Journal: Front Pediatr Date: 2021-12-09 Impact factor: 3.418